INJEX Pharma
| INJEX Pharma AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| founding | 2002 |
| resolution | May 13, 2015 |
| Reason for dissolution | insolvency |
| Seat | Berlin , Germany |
| management | Andy Rösch, CEO |
| Branch | Medical technology |
| Website | www.injex.de |
The INJEX Pharma AG was a manufacturer of syringes without a needle . In the cosmetics application area, active ingredients such as z. B. Hyaluron .
The needleless syringes were also made for veterinary use. It was mainly used in dogs and cats with diabetes or under local anesthesia .
Society and history
INJEX Pharma was a stock corporation, listed on the Frankfurt Stock Exchange since 2008 . In 2011 she took over the business of the former Rösch AG with needle-free syringes. It was founded in 2002 as Rösch & Frey GmbH.
Business activity
The administration was based in Berlin and the main sales markets were, besides Germany, the USA, Canada, Australia and South America. The company had to file for bankruptcy at the district court in Berlin-Charlottenburg on February 12, 2015. The company was then dissolved on May 13, 2015.
Individual evidence
- ↑ DPAG, April 11, 2012: INJEX AG is new to Xetra trading on Deutsche Börse
- ↑ Biotech startups - the merciless struggle for tight money Manager Magazin, March 27, 2015.
- ↑ see HRB 110828 B: Injex Pharma Aktiengesellschaft, Berlin, Buckower Damm 114, 12349 Berlin.